A Large Multicenter Cohort of Ataxia–Telangiectasia: Clinical, Immunologic, Genetic, and Survival Outcomes
European Journal of Neurology · 2026-11 · 33 (11)
DOI: 10.1111/ene.70810 ↗At a glance
Multizentrische Studie in European Journal of Neurology, published online on 2026-11-02. Written by Saba Fekrvand and 32 co-authors. Institution: Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Ir…. Major MEDLINE topics: Ataxia Telangiectasia. 56 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
Ataxia telangiectasia (AT) is a life‐threatening multisystem disorder characterized mainly by neurologic manifestations, infections, and malignancy. We aimed to present a comprehensive analysis of demographic, clinical, immunologic, and genetic features and outcomes of patients with AT in Iran.
Methods
We conducted a retrospective cohort study of 305 registered patients with AT enrolled through a national referral network (2002–2025). Diagnosis was established according to the European Society for Immunodeficiencies criteria.
Results
Mean age at diagnosis and mean age at onset were 72.0 (±46.0) and 25.2 (±35.57) months, respectively. A substantial proportion of patients presented with non‐neurological manifestations as their first clinical feature (43.9%). Among non‐neurological manifestations, pneumonia was the second most common initial manifestation (13%) and the most frequent infectious complication (30.2%). Variants classified as severe under the predicted loss‐of‐function (PVS1) criteria were identified in 104 patients, representing 83.8% of those who underwent genetic evaluation. Immunoglobulin abnormalities were detected in 84.7% of patients. A notable proportion of patients showed class switching recombination defects (45.6%), which were associated with a higher burden of clinical morbidity. Median age at death was 12.8 years (95% CI, 11.0–15.0), and the estimated overall survival rates at 5 and 10 years were 81.6% and 60.2%, respectively. Malignancy (28.9%) and respiratory tract infections (20.0%) were the most common causes of death, respectively.
Conclusion
This large national cohort provides a comprehensive characterization of the clinical, immunologic, and genetic landscape of AT and its determinants of outcome, thereby improving diagnostic recognition, risk stratification, and patient management.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
- Primary Immunodeficiency Diseases Network (PIDNet), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
- Department of Allergy and Clinical Immunology, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Allergy and Clinical Immunology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
- Department of Biology (Molecular and Cellular Biology), Islamic Azad University of Mashhad, Mashhad, Iran.
ORCID profiles: Saba Fekrvand, Ayda Firouzabadi, Pouya Vakilipour, Dorsa Safari, Ali Zarezadeh Mehrabadi, Hossein Esmaeilzadeh, Fatemeh Tarighat Monfared, Reza Salyanchi, Hamid Ahanchian, Arash Kalantari, Nasrin Behniafard, Tooba Momen, Roya Sherkat, Marzieh Tavakol, Alireza Shafiei, Taher Cheraghi, Najmeh Sepahi, Peter Olbrich, Isabelle Meyts, Andrew R Gennery, Hassan Abolhassani, Nima Rezaei, Reza Yazdani
Cite
APA
Fekrvand, S., Firouzabadi, A., Vakilipour, P., Safari, D., Delavari, S., Mehrabadi, A. Z., Chavoshzadeh, Z., Esmaeilzadeh, H., Sharafian, S., DorriMoghaddam, F., Sadeghi-Shabestari, M., Monfared, F. T., Afkham, E. K., Aleyasin, S., Abolnezhadian, F., Salyanchi, R., Ahanchian, H., Kalantari, A., Behniafard, N., …, & Yazdani, R. (2026). A Large Multicenter Cohort of Ataxia–Telangiectasia: Clinical, Immunologic, Genetic, and Survival Outcomes. European Journal of Neurology, 33(11). https://doi.org/10.1111/ene.70810
Vancouver
Fekrvand S, Firouzabadi A, Vakilipour P, Safari D, Delavari S, Mehrabadi AZ, et al. A Large Multicenter Cohort of Ataxia–Telangiectasia: Clinical, Immunologic, Genetic, and Survival Outcomes. European Journal of Neurology. 2026;33(11). doi:10.1111/ene.70810
BibTeX
@article{Fekrvand2026,
author = {Fekrvand, Saba and Firouzabadi, Ayda and Vakilipour, Pouya and Safari, Dorsa and Delavari, Samaneh and Mehrabadi, Ali Zarezadeh and Chavoshzadeh, Zahra and Esmaeilzadeh, Hossein and Sharafian, Samin and DorriMoghaddam, Farahnaz and Sadeghi-Shabestari, Mahnaz and Monfared, Fatemeh Tarighat and Afkham, Ehsan Khoshnezhad and Aleyasin, Soheila and Abolnezhadian, Farhad and Salyanchi, Reza and Ahanchian, Hamid and Kalantari, Arash and Behniafard, Nasrin and Momen, Tooba and Sherkat, Roya and Tavakol, Marzieh and Barzamini, Sahar and Shafiei, Alireza and Cheraghi, Taher and Vosughimotlagh, Ahmad and Sepahi, Najmeh and Olbrich, Peter and Meyts, Isabelle and Gennery, Andrew R and Abolhassani, Hassan and Rezaei, Nima and Yazdani, Reza},
title = {A Large Multicenter Cohort of Ataxia–Telangiectasia: Clinical, Immunologic, Genetic, and Survival Outcomes},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {11},
doi = {10.1111/ene.70810}
}
EUVIMED